Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.

ABSTRACT:

Background

Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-line immune checkpoint inhibitor (ICI) combinations have demonstrated a significant survival benefit.

Methods

A systematic search of the published and presented literature was performed to identify phase III trials assessing ICI combination regimens in RCC using search terms 'immune checkpoint inhibitors' AND 'renal cell carcinoma,' AND 'advanced'.

Results

Six phase III trials showed significant benefits for ICI combinations compared with sunitinib. Nivolumab plus ipilimumab s

SUBMITTER: Lalani AA 

PROVIDER: S-EPMC9244935 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature